```html

Zollinger‑Ellison Syndrome‑Associated Gastritis

Overview

Zollinger‑Ellison syndrome (ZES) is a rare neuroendocrine disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach’s parietal cells to secrete large amounts of gastric acid. When this hyper‑acidic environment repeatedly irritates the gastric mucosa, patients develop gastritis secondary to Zollinger‑Ellison syndrome. The gastritis can be erosive or ulcerative and is a major source of pain and bleeding in ZES.

• Who it affects: Adults of any age, but most cases are diagnosed between 30‑60 years. Both sexes are affected equally, although a slight male predominance (≈55 %) has been reported.
• Prevalence: Gastrinomas are the second most common functional pancreatic neuroendocrine tumor, occurring in about 1‑3 per million people per year. ZES accounts for roughly 0.1 %–0.3 % of all cases of peptic ulcer disease.
• Associated conditions: About 25 % of ZES patients have multiple endocrine neoplasia type 1 (MEN‑1), an inherited syndrome that also predisposes to parathyroid and pituitary tumors.

Symptoms

Because the excess acid affects the entire upper gastrointestinal (GI) tract, symptoms can be widespread. Not all patients experience every sign.

Gastro‑intestinal symptoms

• Severe epigastric pain: Burning or gnawing pain that worsens 1–3 hours after meals or during the night.
• Refractory peptic ulcers: Ulcers that fail to heal despite standard proton‑pump inhibitor (PPI) therapy.
• Gastritis: Erythema, edema, and erosions of the stomach lining, often presenting as dyspepsia.
• Diarrhea: Occurs in up to 40 % of patients due to acid inactivation of pancreatic enzymes and bile salts.
• Steatorrhea (fatty stools): Malabsorption from pancreatic enzyme inactivation.
• Nausea & vomiting: May be triggered by ulcer pain or gastric outlet obstruction.
• Gastrointestinal bleeding: Hematemesis or melena from ulcer erosion.

Systemic symptoms

• Weight loss: From malabsorption, chronic pain, and reduced intake.
• Fatigue & anemia: Chronic blood loss can lead to iron‑deficiency anemia.
• Heartburn & acid reflux: Due to high gastric acid volume.

Causes and Risk Factors

Primary cause

ZES is caused by gastrin‑secreting neuroendocrine tumors (gastrinomas). The majority (≈60‑90 %) arise in the duodenum, while the remainder are found in the pancreas or, rarely, in lymph nodes.

Pathophysiology

1. Gastrinoma → uncontrolled gastrin release.
2. Gastrin → stimulates parietal cells via the CCK‑B receptor.
3. Parietal cells → massive hydrochloric acid output (up to 10× normal).
4. Acid overload → mucosal injury → gastritis, ulceration, and sometimes perforation.

Risk factors

• MEN‑1 syndrome: Inherited mutation of the MEN1 gene; 20‑30 % of ZES patients have this condition.
• Family history of gastrinomas: Rare familial cases have been documented.
• Chronic atrophic gastritis or Helicobacter pylori infection: May increase gastric vulnerability, though they do not cause ZES.
• Age & gender: Slight male predominance and peak incidence in middle adulthood.

Diagnosis

Diagnosing ZES‑associated gastritis requires confirming both hypergastrinemia and acid hypersecretion, then locating the gastrinoma.

Initial laboratory assessment

• Fasting serum gastrin level: Values > 1,000 pg/mL are highly suggestive; levels > 150 pg/mL with a gastric pH < 2 support the diagnosis.
• Secretin stimulation test: Administration of 0.2 U/kg secretin causes a paradoxical rise in gastrin (> 120 pg/mL) in ZES.
• Gastric acid output: 24‑hour gastric acid collection ( > 15 mEq/hour is abnormal).
• Complete blood count (CBC): To detect anemia from chronic bleeding.

Imaging studies

• Endoscopic ultrasound (EUS): High sensitivity for small duodenal gastrinomas.
• Multiphasic contrast‑enhanced CT or MRI: Detects larger tumors and metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT: Gold standard for locating neuroendocrine tumors because gastrinomas express somatostatin receptors.
• Upper endoscopy (EGD): Visualizes gastritis, ulcerations, and can obtain biopsies to rule out H. pylori or malignancy.

Diagnostic criteria (summary)

1. Fasting gastrin > 150 pg/mL + low gastric pH (< 2) or positive secretin test.
2. Demonstration of a gastrin‑producing tumor on imaging.
3. Exclusion of other causes of hypergastrinemia (e.g., chronic atrophic gastritis, PPI use).

Treatment Options

Therapy targets two goals: control gastric acid secretion and eradicate or control the gastrinoma.

Acid‑suppression therapy (first line)

• High‑dose proton pump inhibitors (PPIs): Omeprazole 40–80 mg daily, or equivalent (e.g., esomeprazole 40 mg). PPIs are the most effective agents; doses may be titrated to maintain gastric pH > 4.
• H2‑receptor antagonists: Can be added if PPIs alone are insufficient, though tolerance often develops.
• Potassium‑competitive acid blockers (PCABs): Such as vonoprazan (available in some countries) may offer rapid, potent acid control.

Targeted therapy for the tumor

• Surgical resection: Curative for localized gastrinomas; pancreaticoduodenectomy or enucleation depending on location.
• Somatostatin analogues: Octreotide or lanreotide can suppress gastrin release and are especially useful in metastatic disease.
• Peptide receptor radionuclide therapy (PRRT): 177Lu‑DOTATATE for patients with somatostatin‑receptor positive tumors.
• Chemotherapy / targeted agents: Everolimus or sunitinib may be considered for progressive metastatic disease.

Lifestyle & supportive measures

• Avoid NSAIDs, aspirin, and other ulcerogenic drugs.
• Limit alcohol and caffeine, which stimulate acid secretion.
• Small, frequent meals rather than large meals to reduce gastric distension.
• Maintain adequate hydration; consider oral rehydration solutions if diarrhea is prominent.
• Supplement iron, vitamin B12, and fat‑soluble vitamins if malabsorption is documented.

Living with Zollinger‑Ellison Syndrome‑Associated Gastritis

Daily management tips

1. Medication adherence: Take PPIs exactly as prescribed (usually before breakfast). Use a medication diary or smartphone reminder.
2. Regular follow‑up: Schedule endoscopy or imaging every 6–12 months to monitor ulcer healing and tumor status.
3. Dietary adjustments:
   • Choose low‑fat, low‑spice foods.
   • Incorporate bland proteins (e.g., poultry, tofu), cooked vegetables, and non‑citrus fruits.
   • Stay upright for at least 30 minutes after meals to reduce reflux.
4. Monitor stool and weight: Persistent diarrhea, black/tarry stools, or unexplained weight loss warrants prompt evaluation.
5. Stress management: Chronic pain can exacerbate symptoms; consider relaxation techniques, yoga, or counseling.
6. Vaccinations: If you receive somatostatin analogues or PRRT, stay up‑to‑date with flu and pneumococcal vaccines because of potential immunosuppression.

Psychosocial support

Living with a rare chronic condition can be isolating. Connect with patient‑advocacy groups such as the Neuroendocrine Tumor Research Foundation or local support networks. Mental‑health counseling is recommended if anxiety or depression develop.

Prevention

Because ZES is driven by tumor biology, primary prevention is limited. However, you can reduce secondary complications:

• Never self‑medicate with over‑the‑counter PPIs for long periods without medical supervision—chronic use can mask early symptoms.
• Eradicate Helicobacter pylori if present; co‑infection can worsen gastritis.
• Adopt a ulcer‑friendly lifestyle: avoid smoking, limit alcohol, and steer clear of NSAIDs.
• For patients with MEN‑1, regular genetic counseling and surveillance imaging can detect gastrinomas early.

Complications

If left untreated or poorly controlled, ZES‑associated gastritis can lead to serious outcomes:

• Refractory peptic ulcer disease: Ulcers that bleed, perforate, or cause gastric outlet obstruction.
• Upper GI bleeding: May require transfusion or endoscopic hemostasis.
• Gastric outlet obstruction: Resulting from edema or ulcer scarring; may need dilatation or surgery.
• Malnutrition & electrolyte disturbances: Chronic diarrhea and acid inactivation of pancreatic enzymes.
• Metastatic gastrinoma: Approximately 25‑35 % of patients develop liver or lymph‑node metastases, which worsen prognosis.
• Gastric neuroendocrine (carcinoid) tumors: Chronic hyper‑gastrinemia can stimulate enterochromaffin‑like cell hyperplasia, potentially progressing to carcinoids.

When to Seek Emergency Care

---

Sources: Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American College of Gastroenterology, World Health Organization, Cleveland Clinic, Journal of Clinical Endocrinology & Metabolism (2022), Gastroenterology (2021).

```